Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
  • Current Issue
  • Past Issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Author's Takes
  • Reviews
    • View all reviews ...
    • 100th Anniversary of Insulin's Discovery (Jan 2021)
    • Hypoxia-inducible factors in disease pathophysiology and therapeutics (Oct 2020)
    • Latency in Infectious Disease (Jul 2020)
    • Immunotherapy in Hematological Cancers (Apr 2020)
    • Big Data's Future in Medicine (Feb 2020)
    • Mechanisms Underlying the Metabolic Syndrome (Oct 2019)
    • Reparative Immunology (Jul 2019)
    • View all review series ...
  • Viewpoint
  • Collections
    • Recently published
    • In-Press Preview
    • Commentaries
    • Concise Communication
    • Editorials
    • Viewpoint
    • Top read articles
  • Clinical Medicine
  • JCI This Month
    • Current issue
    • Past issues

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Author's Takes
  • Recently published
  • In-Press Preview
  • Commentaries
  • Concise Communication
  • Editorials
  • Viewpoint
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Alerts
  • Advertising/recruitment
  • Subscribe
  • Contact
Antibiotic treatment–induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia
Oliver H. Robak, … , Catherine Chaput, Bastian Opitz
Oliver H. Robak, … , Catherine Chaput, Bastian Opitz
Published May 17, 2018
Citation Information: J Clin Invest. 2018;128(8):3535-3545. https://doi.org/10.1172/JCI97065.
View: Text | PDF
Research Article Infectious disease

Antibiotic treatment–induced secondary IgA deficiency enhances susceptibility to Pseudomonas aeruginosa pneumonia

  • Text
  • PDF
Abstract

Broad-spectrum antibiotics are widely used with patients in intensive care units (ICUs), many of whom develop hospital-acquired infections with Pseudomonas aeruginosa. Although preceding antimicrobial therapy is known as a major risk factor for P. aeruginosa–induced pneumonia, the underlying mechanisms remain incompletely understood. Here we demonstrate that depletion of the resident microbiota by broad-spectrum antibiotic treatment inhibited TLR-dependent production of a proliferation-inducing ligand (APRIL), resulting in a secondary IgA deficiency in the lung in mice and human ICU patients. Microbiota-dependent local IgA contributed to early antibacterial defense against P. aeruginosa. Consequently, P. aeruginosa–binding IgA purified from lamina propria culture or IgA hybridomas enhanced resistance of antibiotic-treated mice to P. aeruginosa infection after transnasal substitute. Our study provides a mechanistic explanation for the well-documented risk of P. aeruginosa infection following antimicrobial therapy, and we propose local administration of IgA as a novel prophylactic strategy.

Authors

Oliver H. Robak, Markus M. Heimesaat, Andrey A. Kruglov, Sandra Prepens, Justus Ninnemann, Birgitt Gutbier, Katrin Reppe, Hubertus Hochrein, Mark Suter, Carsten J. Kirschning, Veena Marathe, Jan Buer, Mathias W. Hornef, Markus Schnare, Pascal Schneider, Martin Witzenrath, Stefan Bereswill, Ulrich Steinhoff, Norbert Suttorp, Leif E. Sander, Catherine Chaput, Bastian Opitz

×

Figure 1

Antibiotic-mediated microbiota depletion impairs antibacterial defense against P. aeruginosa.

Options: View larger image (or click on image) Download as PowerPoint
Antibiotic-mediated microbiota depletion impairs antibacterial defense a...
(A–D) Conventionally colonized mice (Conv) and mice that were treated with an antibiotic cocktail for 6–8 weeks (ABx) were infected with P. aeruginosa. (A) Bacterial loads in BALF (n = 9), (B) lung tissue (n = 11 for Conv mice; n = 9 for ABx mice), and (C) blood (n = 11 for Conv mice; n = 9 for ABx mice) were counted at the indicated time points, or (D) survival was monitored (n = 11 for Conv mice; n = 12 for ABx mice). (E–M) Mice were intranasally infected with P. aeruginosa or treated with PBS for 6 hours. Production of inflammatory mediators was measured by ELISA (n = 10 for uninfected Conv and ABx mice; n = 10 for infected Conv mice; n = 11 for infected ABx mice) and qRT-PCR (n = 8 for uninfected Conv and ABx mice; n = 10 for infected Conv mice; n = 9 for infected ABx mice). (N and O) Alveolar macrophages (n = 9 for uninfected Conv and ABx mice; n = 9 for infected Conv mice; n = 7 for infected ABx mice) and neutrophils (n = 9 for uninfected Conv and ABx mice; n = 9 for infected Conv mice; n = 8 for infected ABx mice) were counted by FACS analysis after staining of BALF samples. (P) Lung vascular permeability of control and microbiota-depleted animals was measured by Evans blue dye leakage in the lungs (n = 8 for Conv; n = 8 for ABx mice). Mann-Whitney U tests were applied to the data set, except for the survival curve (D), which was submitted to log-rank test. Values are mean ± SD. *P < 0.05, **P < 0.01, ***P < 0.005.
Follow JCI:
Copyright © 2021 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts